Enhancement of drug delivery in prostate tumor in vivo using MR guided focused ultrasound (MRgHIFU)

Lili Chen, Z. Mu, P. Hachem, C. M. Ma, Alan Pollack

Research output: Chapter in Book/Report/Conference proceedingConference contribution

3 Citations (Scopus)

Abstract

The purpose of this work is to investigate the effects of pulsed focused ultrasound on the enhancement of 3H-Docetaxel delivery in prostate tumors in vivo. Human prostate cancer LNCaP cells (5 x 105) in 24 ml medium were injected into the prostates of male nude mice. When tumor reached the size of 160 ± 10 mm3 on MRI, HIFU treatment was performed using an InSightec ExAblate 2000 system with a 1.5 T GE MR scanner. The animals were randomly divided into 3 groups (n=8 per group): Group 1, HIFU treatment + 3H-Docetaxel; Group 2, HIFU treatment only and Group 3, as control. For group 1, each mouse was treated with pulsed HIFU under general anesthesia using MR guidance. Immediately after, HIFU treated animals received a single dose of i.v injection of Docetaxel at 15 mg/kg mixed with 3H- Docetaxel at 50 uCi/kg in total volume of 150 μl. Animals in group 2 were treated the same as in group one with the exception of HIFU treatment. Animals were sacrificed 30 minutes after i.v injections and tumors were removed and processed. The radioactivity of 3H-docetaxel in the tumor tissue was quantitatively measured by a liquid scintillation counter. Results showed that all animals tolerated the MRgHIFU treatment well. There were no treatment-related adverse events including skin toxicity. Our data show increased 3H-docetaxel concentration in tumor in the MRgHIFU treated group (1079 ± 132 cmp/75 mg) vs. those without MRgHIFU treatment (524 ± 201 cmp/75 mg) with P = 0.037. We have demonstrated the enhancement of 3H-Docetaxel uptake in implanted prostate tumors with MRgHIFU in vivo. Future studies will be carried out on the efficacy of Docetaxel combined with radiotherapy (RT) to inhibit prostate cancer growth in vivo.

Original languageEnglish
Title of host publicationIFMBE Proceedings
Pages341-344
Number of pages4
Volume25
Edition6
DOIs
StatePublished - Dec 1 2009
EventWorld Congress on Medical Physics and Biomedical Engineering - Surgery, Minimal Invasive Interventions, Endoscopy and Image Guided Therapy - Munich, Germany
Duration: Sep 7 2009Sep 12 2009

Other

OtherWorld Congress on Medical Physics and Biomedical Engineering - Surgery, Minimal Invasive Interventions, Endoscopy and Image Guided Therapy
CountryGermany
CityMunich
Period9/7/099/12/09

Fingerprint

docetaxel
Drug delivery
Tumors
Ultrasonics
Animals
Scintillation counters
Radioactivity
Radiotherapy
Magnetic resonance imaging
Toxicity
Skin
Tissue

Keywords

  • Drug delivery
  • In vivo
  • Mouse model
  • MRgHIFU
  • Prostate cancer

ASJC Scopus subject areas

  • Biomedical Engineering
  • Bioengineering

Cite this

Enhancement of drug delivery in prostate tumor in vivo using MR guided focused ultrasound (MRgHIFU). / Chen, Lili; Mu, Z.; Hachem, P.; Ma, C. M.; Pollack, Alan.

IFMBE Proceedings. Vol. 25 6. ed. 2009. p. 341-344.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Chen, L, Mu, Z, Hachem, P, Ma, CM & Pollack, A 2009, Enhancement of drug delivery in prostate tumor in vivo using MR guided focused ultrasound (MRgHIFU). in IFMBE Proceedings. 6 edn, vol. 25, pp. 341-344, World Congress on Medical Physics and Biomedical Engineering - Surgery, Minimal Invasive Interventions, Endoscopy and Image Guided Therapy, Munich, Germany, 9/7/09. https://doi.org/10.1007/978-3-642-03906-5-94
Chen, Lili ; Mu, Z. ; Hachem, P. ; Ma, C. M. ; Pollack, Alan. / Enhancement of drug delivery in prostate tumor in vivo using MR guided focused ultrasound (MRgHIFU). IFMBE Proceedings. Vol. 25 6. ed. 2009. pp. 341-344
@inproceedings{e4220d2d73c84852a7b068b28c3e493d,
title = "Enhancement of drug delivery in prostate tumor in vivo using MR guided focused ultrasound (MRgHIFU)",
abstract = "The purpose of this work is to investigate the effects of pulsed focused ultrasound on the enhancement of 3H-Docetaxel delivery in prostate tumors in vivo. Human prostate cancer LNCaP cells (5 x 105) in 24 ml medium were injected into the prostates of male nude mice. When tumor reached the size of 160 ± 10 mm3 on MRI, HIFU treatment was performed using an InSightec ExAblate 2000 system with a 1.5 T GE MR scanner. The animals were randomly divided into 3 groups (n=8 per group): Group 1, HIFU treatment + 3H-Docetaxel; Group 2, HIFU treatment only and Group 3, as control. For group 1, each mouse was treated with pulsed HIFU under general anesthesia using MR guidance. Immediately after, HIFU treated animals received a single dose of i.v injection of Docetaxel at 15 mg/kg mixed with 3H- Docetaxel at 50 uCi/kg in total volume of 150 μl. Animals in group 2 were treated the same as in group one with the exception of HIFU treatment. Animals were sacrificed 30 minutes after i.v injections and tumors were removed and processed. The radioactivity of 3H-docetaxel in the tumor tissue was quantitatively measured by a liquid scintillation counter. Results showed that all animals tolerated the MRgHIFU treatment well. There were no treatment-related adverse events including skin toxicity. Our data show increased 3H-docetaxel concentration in tumor in the MRgHIFU treated group (1079 ± 132 cmp/75 mg) vs. those without MRgHIFU treatment (524 ± 201 cmp/75 mg) with P = 0.037. We have demonstrated the enhancement of 3H-Docetaxel uptake in implanted prostate tumors with MRgHIFU in vivo. Future studies will be carried out on the efficacy of Docetaxel combined with radiotherapy (RT) to inhibit prostate cancer growth in vivo.",
keywords = "Drug delivery, In vivo, Mouse model, MRgHIFU, Prostate cancer",
author = "Lili Chen and Z. Mu and P. Hachem and Ma, {C. M.} and Alan Pollack",
year = "2009",
month = "12",
day = "1",
doi = "10.1007/978-3-642-03906-5-94",
language = "English",
isbn = "9783642039058",
volume = "25",
pages = "341--344",
booktitle = "IFMBE Proceedings",
edition = "6",

}

TY - GEN

T1 - Enhancement of drug delivery in prostate tumor in vivo using MR guided focused ultrasound (MRgHIFU)

AU - Chen, Lili

AU - Mu, Z.

AU - Hachem, P.

AU - Ma, C. M.

AU - Pollack, Alan

PY - 2009/12/1

Y1 - 2009/12/1

N2 - The purpose of this work is to investigate the effects of pulsed focused ultrasound on the enhancement of 3H-Docetaxel delivery in prostate tumors in vivo. Human prostate cancer LNCaP cells (5 x 105) in 24 ml medium were injected into the prostates of male nude mice. When tumor reached the size of 160 ± 10 mm3 on MRI, HIFU treatment was performed using an InSightec ExAblate 2000 system with a 1.5 T GE MR scanner. The animals were randomly divided into 3 groups (n=8 per group): Group 1, HIFU treatment + 3H-Docetaxel; Group 2, HIFU treatment only and Group 3, as control. For group 1, each mouse was treated with pulsed HIFU under general anesthesia using MR guidance. Immediately after, HIFU treated animals received a single dose of i.v injection of Docetaxel at 15 mg/kg mixed with 3H- Docetaxel at 50 uCi/kg in total volume of 150 μl. Animals in group 2 were treated the same as in group one with the exception of HIFU treatment. Animals were sacrificed 30 minutes after i.v injections and tumors were removed and processed. The radioactivity of 3H-docetaxel in the tumor tissue was quantitatively measured by a liquid scintillation counter. Results showed that all animals tolerated the MRgHIFU treatment well. There were no treatment-related adverse events including skin toxicity. Our data show increased 3H-docetaxel concentration in tumor in the MRgHIFU treated group (1079 ± 132 cmp/75 mg) vs. those without MRgHIFU treatment (524 ± 201 cmp/75 mg) with P = 0.037. We have demonstrated the enhancement of 3H-Docetaxel uptake in implanted prostate tumors with MRgHIFU in vivo. Future studies will be carried out on the efficacy of Docetaxel combined with radiotherapy (RT) to inhibit prostate cancer growth in vivo.

AB - The purpose of this work is to investigate the effects of pulsed focused ultrasound on the enhancement of 3H-Docetaxel delivery in prostate tumors in vivo. Human prostate cancer LNCaP cells (5 x 105) in 24 ml medium were injected into the prostates of male nude mice. When tumor reached the size of 160 ± 10 mm3 on MRI, HIFU treatment was performed using an InSightec ExAblate 2000 system with a 1.5 T GE MR scanner. The animals were randomly divided into 3 groups (n=8 per group): Group 1, HIFU treatment + 3H-Docetaxel; Group 2, HIFU treatment only and Group 3, as control. For group 1, each mouse was treated with pulsed HIFU under general anesthesia using MR guidance. Immediately after, HIFU treated animals received a single dose of i.v injection of Docetaxel at 15 mg/kg mixed with 3H- Docetaxel at 50 uCi/kg in total volume of 150 μl. Animals in group 2 were treated the same as in group one with the exception of HIFU treatment. Animals were sacrificed 30 minutes after i.v injections and tumors were removed and processed. The radioactivity of 3H-docetaxel in the tumor tissue was quantitatively measured by a liquid scintillation counter. Results showed that all animals tolerated the MRgHIFU treatment well. There were no treatment-related adverse events including skin toxicity. Our data show increased 3H-docetaxel concentration in tumor in the MRgHIFU treated group (1079 ± 132 cmp/75 mg) vs. those without MRgHIFU treatment (524 ± 201 cmp/75 mg) with P = 0.037. We have demonstrated the enhancement of 3H-Docetaxel uptake in implanted prostate tumors with MRgHIFU in vivo. Future studies will be carried out on the efficacy of Docetaxel combined with radiotherapy (RT) to inhibit prostate cancer growth in vivo.

KW - Drug delivery

KW - In vivo

KW - Mouse model

KW - MRgHIFU

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=77949393612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949393612&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-03906-5-94

DO - 10.1007/978-3-642-03906-5-94

M3 - Conference contribution

SN - 9783642039058

VL - 25

SP - 341

EP - 344

BT - IFMBE Proceedings

ER -